TABLE 3-11 Other Rx Treatments



Arm (N)

Handling of Dropouts and % Completed Tx by Arm

PTSD Outcome Measure

Heresco-Levy et al., 2002

Male, accident, physical abuse

Total (11)

64% overall


D-cycloserine (6)


PL (5)


Crossover Study





Kaplan et al., 1996

Male and Female, mixed trauma

Total (17)



Inositol (NR)

No treatment of missing values


Crossover Study





aIn the population column, male alone or female alone denotes that at least 80% of the study population was male or female. If only one trauma type is listed, at least 80% of the study population reported that type of trauma.

bPTSD outcome measure change data were obtained either directly from the study, when provided, or by subtracting data reported at treatment completion (not follow-up data) from

Conclusion: The committee concludes that the evidence is inadequate to determine the efficacy of naltrexone, cycloserine, or inositol in the treatment of PTSD.

Exclusion Notes

Several case studies or series, open-label trials, uncontrolled trials, and RCTs have been conducted on various pharmacotherapies not included in the classes outlined above. Several other studies were excluded, and the reasons are briefly described here. In one RCT only 36 percent of the sample was diagnosed with PTSD so was excluded (Petrakis et al., 2006). One study compared tianeptine with fluoxetine and moclobemide, but had no placebo group so was excluded (Onder et al., 2006). Dow and Kline (1997) was excluded because it used several different drugs, had no comparison group or blinding, adverse events were not distinguished from efficacy failures, and it had many uncontrolled variables. A study examining sildenafil was excluded, because it only focused on erectile dysfunction (Orr et al., 2006). A study on naloxone was excluded, because it only looked at pain and not overall PTSD (Pitman et al., 1990). Another study by Pitman and colleagues that was excluded examined PTSD outcomes but the treatment

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement